Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

To determine the anhidrotic area and safety of MEDITOXIN

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anhidrotic Area Hyperhidrosis Skin Diseases Skin and Connective Tissue Diseases Sweat Gland Diseases

Age range

20 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Catholic University St. Paul Hospital

Seoul, Dongdaemun-gu, 130-709, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male adults aged between 20 and 45 years

Exclusion criteria

Subjects not appropriate for participating in this study according to the investigator's opinion

Treatment and study plan

Meditoxin

Drug

injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses

Botox

Drug

injection of Botox into the intradermal of each contralateral upper back in equal doses

Primary outcomes

anhidrotic area

Time frame: week 4

After the ninhydrin sweat test, measure the area of the unstained area

Sponsors and collaborators

Lead sponsor

Medy-Tox

Industry

Registry information

Official study title

Open-Label, Active Controlled, Single-Center, Phase 1 Study to Determine the Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Volunteers

Important dates

Study start: 2018
Primary completion: 2018
Study completion: 2018
First posted: Aug 27, 2018
Registry last updated: Mar 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed